To identify genetic targets whose inhibition restores sensitivity to death receptor ligands, a cell-based high throughput screen was performed using the FasL and TRAIL-resistant prostate cancer cell line PPC-1 and the commercially available Dharmacon siRNA library of 6080 SMARTpools. The gene discussed is FASLG; the disease is prostate carcinoma.